Isthmus Partners LLC decreased its holdings in BioSpecifics Technologies Corp (NASDAQ:BSTC) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,505 shares of the biopharmaceutical company’s stock after selling 384 shares during the period. Isthmus Partners LLC owned about 0.23% of BioSpecifics Technologies Corp worth $817,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. US Bancorp DE grew its position in shares of BioSpecifics Technologies Corp by 1.1% during the 2nd quarter. US Bancorp DE now owns 3,455 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 36 shares in the last quarter. Chicago Equity Partners LLC grew its position in shares of BioSpecifics Technologies Corp by 0.8% during the 2nd quarter. Chicago Equity Partners LLC now owns 13,225 shares of the biopharmaceutical company’s stock worth $655,000 after buying an additional 110 shares in the last quarter. American International Group Inc. grew its position in shares of BioSpecifics Technologies Corp by 7.1% during the 1st quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 222 shares in the last quarter. American Century Companies Inc. grew its position in shares of BioSpecifics Technologies Corp by 1.0% during the 2nd quarter. American Century Companies Inc. now owns 30,461 shares of the biopharmaceutical company’s stock worth $1,508,000 after buying an additional 302 shares in the last quarter. Finally, Prudential Financial Inc. grew its position in shares of BioSpecifics Technologies Corp by 0.5% during the 2nd quarter. Prudential Financial Inc. now owns 65,747 shares of the biopharmaceutical company’s stock worth $3,255,000 after buying an additional 328 shares in the last quarter. Institutional investors and hedge funds own 55.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BioSpecifics Technologies Corp (BSTC) Holdings Trimmed by Isthmus Partners LLC” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/19/biospecifics-technologies-corp-bstc-holdings-trimmed-by-isthmus-partners-llc.html.

BSTC has been the topic of a number of recent research reports. Zacks Investment Research raised BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. BidaskClub downgraded BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, HC Wainwright set a $72.00 price target on BioSpecifics Technologies Corp and gave the stock a “buy” rating in a research report on Thursday, August 10th.

BioSpecifics Technologies Corp (BSTC) traded up 0.17% during trading on Tuesday, hitting $46.60. The stock had a trading volume of 4,509 shares. The company has a market cap of $333.84 million, a P/E ratio of 28.59 and a beta of 1.76. The firm has a 50 day moving average of $46.72 and a 200-day moving average of $50.89. BioSpecifics Technologies Corp has a one year low of $38.89 and a one year high of $58.79.

BioSpecifics Technologies Corp Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.